Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Net Income towards Common Stockholders: 2019-2024

Historic Net Income towards Common Stockholders for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to -$160.9 million.

  • 4D Molecular Therapeutics' Net Income towards Common Stockholders fell 29.73% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.2 million, marking a year-over-year decrease of 45.79%. This contributed to the annual value of -$160.9 million for FY2024, which is 59.53% down from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Net Income towards Common Stockholders of -$160.9 million as of FY2024, which was down 59.53% from -$100.8 million recorded in FY2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Net Income towards Common Stockholders peaked at -$56.7 million during FY2020, and registered a low of -$160.9 million during FY2024.
  • For the 3-year period, 4D Molecular Therapeutics' Net Income towards Common Stockholders averaged around -$123.1 million, with its median value being -$107.5 million (2022).
  • In the last 5 years, 4D Molecular Therapeutics' Net Income towards Common Stockholders climbed by 6.19% in 2023 and then crashed by 59.53% in 2024.
  • 4D Molecular Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$56.7 million in 2020, then declined by 25.80% to -$71.3 million in 2021, then slumped by 50.73% to -$107.5 million in 2022, then grew by 6.19% to -$100.8 million in 2023, then plummeted by 59.53% to -$160.9 million in 2024.